Co-Authors
This is a "connection" page, showing publications co-authored by ROSEMARIE SCHMANDT and MELINDA YATES.
Connection Strength
0.883
-
Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer. bioRxiv. 2024 Jun 11.
Score: 0.241
-
Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release. 2021 11 10; 339:521-530.
Score: 0.200
-
Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila). 2018 08; 11(8):477-490.
Score: 0.158
-
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
Score: 0.045
-
Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel). 2020 Jan 02; 12(1).
Score: 0.044
-
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer. 2017 06; 27(5):854-862.
Score: 0.037
-
Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. Oncology. 2017; 92(2):109-114.
Score: 0.036
-
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
Score: 0.035
-
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecol Oncol. 2014 Apr; 133(1):83-9.
Score: 0.030
-
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013 Dec; 12(12):2847-56.
Score: 0.029
-
Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 2013 Jul; 209(1):24.e1-24.e12.
Score: 0.028